Porcine Vaccine Market Report 2026

The porcine vaccine market size has grown strongly in recent years. It will grow from $2.05 billion in 2025 to $2.25 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to outbreaks of swine diseases, rising pork consumption, development of traditional vaccines, increasing veterinary awareness, expansion of hog farming infrastructure.

The porcine vaccine market size is expected to see strong growth in the next few years. It will grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to growth of recombinant and dna vaccines, adoption of precision veterinary medicine, increased focus on herd immunity programs, technological advancements in vaccine delivery systems, rising government initiatives for livestock health. Major trends in the forecast period include adoption of multi-strain vaccines for pigs, increasing focus on disease prevention in swine herds, rising investments in swine immunization programs, integration of veterinary advisory services with farms, expansion of cold chain infrastructure for vaccine distribution.

The rising pork consumption is expected to drive the growth of the porcine vaccine market in the coming years. Pork consumption refers to the amount of pork meat consumed by individuals or groups within a specific time frame. This consumption has grown alongside the increasing global population and the heightened demand for protein. The porcine vaccine market supports this trend by preventing diseases in pigs, enhancing herd health, and ensuring a consistent supply of safe, high-quality pork products. For example, in July 2024, according to INAPORC (Interprofession Nationale Porcine), a France-based national pork association, pork remained the most consumed meat in France in 2023, at approximately 30.6 kg per person per year. Hence, the growing pork consumption is propelling the porcine vaccine market forward.

Key players in the porcine vaccine market are leveraging strategic partnerships to enhance their research and development capabilities and strengthen their competitive position in the rapidly evolving animal health sector. Such collaborations combine TVG's expertise in vaccine technology with Pirbright's specialization in African swine fever (ASF) research. The objective is to improve vaccine development processes and create innovative solutions to significantly advance swine health. For instance, in May 2024, The Pirbright Institute, a UK-based research organization, partnered with The Vaccine Group (TVG), a UK-based company, to develop a vaccine for African swine fever (ASF). This research focuses on using bovine herpesvirus 4 (BoHV-4) as a foundation to design more effective vaccines, leveraging recent advancements in ASF vaccine research and pig immunology. The project is supported by the U.K.'s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

In July 2024, Merck Animal Health Inc., a US-based company, acquired Elanco for an undisclosed amount. Through this acquisition, Merck Animal Health aims to expand its portfolio by integrating Elanco's expertise in porcine vaccines. Elanco Animal Health Inc., a US-based company, provides a range of porcine vaccines.

Major companies operating in the porcine vaccine market are Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., IDT Biologika GmbH, Biogénesis Bagó, Aptimmune Biologics Inc., Virbac S.A., Vaxxinova International BV, Bioveta a.s., Indian Immunologicals Limited, KM Biologics, Addison Biological Laboratory, Colorado Serum Company, CAHIC China Animal Husbandry Industry Co, Tecon, Hile Bio, WINSUN.

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the porcine vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the porcine vaccine market by raising the cost of imported vaccines, cold chain equipment, and veterinary supplies. Segments such as inactivated and recombinant vaccines are most affected, particularly in regions like North America, Europe, and Asia-Pacific, which rely heavily on imports. While tariffs increase operational costs for manufacturers, they can also promote domestic production, encourage local innovation, and enhance the availability of regionally produced vaccines at competitive prices.

The porcine vaccine market research report is one of a series of new reports that provides porcine vaccine market statistics, including porcine vaccine industry global market size, regional shares, competitors with a porcine vaccine market share, detailed porcine vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the porcine vaccine industry. This porcine vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Porcine vaccines are medical and pharmaceutical treatments designed to enhance the health of pigs by protecting them from various bacteria, viruses, and infections. These vaccines aim to increase the effectiveness of safeguarding pigs from harmful diseases while also improving the production of high-quality meat for human consumption.

In the realm of porcine vaccines, major technologies include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. Inactivated vaccines, for instance, are made from killed or inactivated viruses or bacteria and stimulate an immune response to protect pigs against natural infections. These vaccines are employed to address various diseases such as diarrhea, swine influenza, arthritis, bordatella rhinitis, porcine reproductive and respiratory virus (PRRSV), porcine circovirus-associated disease (PCVAD), and others, commonly utilized in hospitals and pig production farms.

The porcine vaccines market consists of sales of antibacterial vaccines and antiviral vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.